715 related articles for article (PubMed ID: 25600645)
1. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.
Hirata H; Hinoda Y; Shahryari V; Deng G; Nakajima K; Tabatabai ZL; Ishii N; Dahiya R
Cancer Res; 2015 Apr; 75(7):1322-31. PubMed ID: 25600645
[TBL] [Abstract][Full Text] [Related]
2. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
[TBL] [Abstract][Full Text] [Related]
3. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.
Huo Y; Li Q; Wang X; Jiao X; Zheng J; Li Z; Pan X
Oncotarget; 2017 Jul; 8(29):46993-47006. PubMed ID: 28388584
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
Wang D; Ding L; Wang L; Zhao Y; Sun Z; Karnes RJ; Zhang J; Huang H
Oncotarget; 2015 Dec; 6(38):41045-55. PubMed ID: 26516927
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 cooperates with enhancer of zeste homolog 2 to promote hepatocellular carcinoma development by modulating the microRNA-22/Snail family transcriptional repressor 1 axis.
Chen S; Wang G; Tao K; Cai K; Wu K; Ye L; Bai J; Yin Y; Wang J; Shuai X; Gao J; Pu J; Li H
Cancer Sci; 2020 May; 111(5):1582-1595. PubMed ID: 32129914
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2.
Wang X; Sehgal L; Jain N; Khashab T; Mathur R; Samaniego F
J Transl Med; 2016 Dec; 14(1):346. PubMed ID: 27998273
[TBL] [Abstract][Full Text] [Related]
8. MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR-203 and promoting the expression of BIRC5.
Zhang H; Li W; Gu W; Yan Y; Yao X; Zheng J
Cell Prolif; 2019 Sep; 52(5):e12640. PubMed ID: 31250518
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
11. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Koumangoye RB; Andl T; Taubenslag KJ; Zilberman ST; Taylor CJ; Loomans HA; Andl CD
Mol Cancer; 2015 Feb; 14():24. PubMed ID: 25644061
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting β-catenin via Ezh2.
Wang W; Zhu Y; Li S; Chen X; Jiang G; Shen Z; Qiao Y; Wang L; Zheng P; Zhang Y
Oncotarget; 2016 May; 7(18):25668-82. PubMed ID: 27015363
[TBL] [Abstract][Full Text] [Related]
13. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
[TBL] [Abstract][Full Text] [Related]
14. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma.
Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H
Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MALAT1 promotes colorectal cancer development by sponging miR-363-3p to regulate EZH2 expression.
Xie JJ; Li WH; Li X; Ye W; Shao CF
J Biol Regul Homeost Agents; 2019; 33(2):331-343. PubMed ID: 30972996
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR-194-5p/ACVR2B signaling.
Ye Y; Zhang F; Chen Q; Huang Z; Li M
Mol Carcinog; 2019 Feb; 58(2):279-292. PubMed ID: 30334578
[TBL] [Abstract][Full Text] [Related]
18. Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway.
Li Z; Ma Z; Xu X
Oncol Rep; 2019 Feb; 41(2):1113-1121. PubMed ID: 30431104
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of tumor‑derived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.
Jin C; Shi L; Li K; Liu W; Qiu Y; Zhao Y; Zhao B; Li Z; Li Y; Zhu Q
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34278501
[TBL] [Abstract][Full Text] [Related]
20. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10.
Qi Y; Ooi HS; Wu J; Chen J; Zhang X; Tan S; Yu Q; Li YY; Kang Y; Li H; Xiong Z; Zhu T; Liu B; Shao Z; Zhao X
Oncotarget; 2016 Mar; 7(11):12693-703. PubMed ID: 26871474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
